Severe pediatric asthma therapy: Omalizumab-A systematic review and meta-analysis of efficacy and safety profile.

Front Pediatr · 2022 · PMC10020639 · PMID 36937051

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the study by Busse et al., the difference in predicted FEV 1 % values was 0.92 (95% CI, 0.81;2.64) in the omalizumab group, but it did not reach statistical significance ( 16 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.